VEGENICS LIMITED Patent applications |
Patent application number | Title | Published |
20120125348 | AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 05-24-2012 |
20110269146 | Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 11-03-2011 |
20110243912 | Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided. | 10-06-2011 |
20110189170 | Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same - The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject. | 08-04-2011 |
20110142839 | TREATMENT OF PULMONARY EDEMA - The invention relates to a method of treatment of pulmonary edema, comprising the step of administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis or inhibiting VEGF-D activity in the subject. The method may comprise the step of identifying a subject at risk of developing pulmonary edema. The invention also relates to an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity for treating pulmonary edema in a subject. Further, the invention relates to use of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity in the manufacture of a medicament for treating pulmonary edema in a subject. | 06-16-2011 |
20110059890 | EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 03-10-2011 |
20100041605 | Use of VEGF-C or VEGF-D in Reconstructive Surgery - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 02-18-2010 |
20090318352 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins - The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors. | 12-24-2009 |
20090155268 | Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided. | 06-18-2009 |
20090155252 | CHIMERIC ANTI-VEGF-D ANTIBODIES AND HUMANIZED ANTI-VEGF-D ANTIBODIES AND METHODS OF USING SAME - The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject. | 06-18-2009 |
20090087905 | VEGF-D polynucleotides and methods of use - VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications. | 04-02-2009 |
20080317723 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS - The present invention is directed to methods and compositions for isolating lymphatic endothelial cells from a mixed population of cells. More particularly, the inventors have found that certain antibodies that recognize the extracellular domain of VEGFR-3 can be used to specifically isolated lymphatic endothelial cells substantially free of other contaminating non-lymphatic endothelial cells. Methods and compositions for producing such cells and using such cells are described. | 12-25-2008 |
20080267956 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant. | 10-30-2008 |
20080267924 | AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 10-30-2008 |